Nature reports an exciting development that a heterogeneous group of diseases can be treated with incretin-based therapies, even in the absence of preclinical supporting data
N-acetyl-cysteine as effective and safe chelating agent in metal-on-metal hip-implanted patients: two cases
While these reports primarily involve compounded injectables rather than patches, they illustrate the dangers of unregulated products in the GLP-1 space
This participant was already taking tirzepatide when she enrolled in the trial, but before any stimulation was delivered, giving us a unique opportunity to make foundational observations about how the drug alters brain signals. At first, results were promising: As patient 3s tirzepatide levels reached full dosage, craving-linked NAc activity in her brain went dormant and she had no obsessive thoughts about food
Ginkgo biloba is a herb that comes from a tree native to China
The study also focused only on semaglutide, and the findings cannot be immediately generalized to other GLP-1 drugs
